Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CureVac N.V. CVAC
$8.43
-$0.24 (-2.88%)
На 18:02, 12 мая 2023
+244.01%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2034723780.00000000
-
week52high
20.06
-
week52low
5.63
-
Revenue
67420000
-
P/E TTM
-17
-
Beta
2.88059700
-
EPS
-1.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 мая 2023 г. в 10:59
Описание компании
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Deutsche Bank | Hold | 31 дек 2021 г. | |
| Deutsche Bank | Hold | 22 окт 2021 г. | |
| B of A Securities | Neutral | Buy | 17 июн 2021 г. |
| Guggenheim | Buy | 26 апр 2021 г. | |
| Credit Suisse | Underperform | Neutral | 10 дек 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
UBS: CureVac has a ‘potentially competitive mRNA platform'
Market Watch
19 янв 2023 г. в 13:56
CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities analysts, who upgraded the company's stock to Buy from Neutral on Thursday. They also raised the price target to $18 from $8.
UBS reveals a biotech stock that can nearly double from here
Invezz
19 янв 2023 г. в 13:06
Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.
7 Biotech Stocks That Will Make You Rich in 10 Years
InvestorPlace
18 янв 2023 г. в 15:44
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.
Why CureVac's Shares Jumped on Tuesday
The Motley Fool
10 янв 2023 г. в 16:16
The stock rose for the third consecutive day.
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response
Market Watch
09 янв 2023 г. в 10:39
A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.